“…11 Presented in this month's issue of JBI Evidence Synthesis, our team conducted a systematic review that pooled results from 11 studies that demonstrated a small but consistent increase in blood glucose levels among patients with diabetes who received a single intravenous dose of 4 to 10 mg of dexamethasone. 12 The clinical implications of this increase in blood glucose levels is likely negligible and easily managed with exogenous insulin administration if required, 13 reinforcing the safety and effectiveness of combination therapy, including dexamethasone. Additional benefits beyond alleviation of PONV to support administration of dexamethasone include reduced systemic inflammation and pain reduction.…”